NASDAQ:ESPR Esperion Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Esperion Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $37.52 +1.47 (+4.08 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$35.60Now: $37.52▼$37.7050-Day Range$31.18MA: $35.79▼$39.5252-Week Range$24.82Now: $37.52▼$76.98Volume322,037 shsAverage Volume729,680 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/ABeta1.82 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.75, Esperion Therapeutics has a forecasted upside of 117.9% from its current price of $37.52.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesEsperion Therapeutics has received 562 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEsperion Therapeutics has received 436 “underperform” votes. (Add your “underperform” vote.)Community SentimentEsperion Therapeutics has received 56.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote “Outperform” if you believe ESPR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Esperion Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to decrease in the coming year, from ($4.26) to ($8.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEsperion Therapeutics has a P/B Ratio of 51.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.23 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR Previous Symbol CUSIPN/A CIK1434868 Webwww.esperion.com Phone734-887-3903Debt Debt-to-Equity RatioN/A Current Ratio3.83 Quick Ratio3.73Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$148.36 million Price / Sales7.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book51.40Profitability EPS (Most Recent Fiscal Year)($3.59) Net Income$-97,170,000.00 Net Margins-38.86% Return on Equity-271.49% Return on Assets-34.28%Miscellaneous Employees76 Outstanding Shares27,825,000Market Cap$1.04 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $37.52 +1.47 (+4.08 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ESPR News and Ratings via Email Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions How has Esperion Therapeutics' stock price been impacted by COVID-19 (Coronavirus)? Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ESPR shares have decreased by 12.6% and is now trading at $37.52. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Esperion Therapeutics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Esperion Therapeutics. When is Esperion Therapeutics' next earnings date? Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Esperion Therapeutics. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics Inc (NASDAQ:ESPR) released its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported $4.32 earnings per share for the quarter, beating the consensus estimate of $2.13 by $2.19. The biopharmaceutical company had revenue of $212.24 million for the quarter, compared to analysts' expectations of $147.97 million. Esperion Therapeutics had a negative net margin of 38.86% and a negative return on equity of 271.49%. The company's quarterly revenue was up 21557.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.01) EPS. View Esperion Therapeutics' earnings history. What price target have analysts set for ESPR? 12 equities research analysts have issued 12 month price objectives for Esperion Therapeutics' stock. Their forecasts range from $42.00 to $191.00. On average, they expect Esperion Therapeutics' stock price to reach $81.75 in the next year. This suggests a possible upside of 117.9% from the stock's current price. View analysts' price targets for Esperion Therapeutics. Who are some of Esperion Therapeutics' key competitors? Some companies that are related to Esperion Therapeutics include MorphoSys (MOR), Evotec (EVTCY), Legend Biotech (LEGN), Allakos (ALLK), FibroGen (FGEN), Biohaven Pharmaceutical (BHVN), Turning Point Therapeutics (TPTX), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), HYPERA S A/S (HYPMY), Insmed (INSM), Global Blood Therapeutics (GBT), Principia Biopharma (PRNB), SAGE Therapeutics (SAGE) and PTC Therapeutics (PTCT). View all competitors. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), Gilead Sciences (GILD), Ship Finance International (SFL), Alibaba Group (BABA), BioMarin Pharmaceutical (bmrn) and Boeing (BA). Who are Esperion Therapeutics' key executives? Esperion Therapeutics' management team includes the following people: Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)Mr. Alexander Duke Schwartz, Sr. Director of Investor RelationsMs. Marianne Andreach, Sr. VP What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (19.06%), Vanguard Group Inc. (8.49%), Wasatch Advisors Inc. (4.51%), Platinum Investment Management Ltd. (3.08%), Avidity Partners Management LP (2.01%) and Rhenman & Partners Asset Management AB (1.54%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View institutional ownership trends for Esperion Therapeutics. Which major investors are selling Esperion Therapeutics stock? ESPR stock was sold by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Rhenman & Partners Asset Management AB, Vanguard Group Inc., Candriam Luxembourg S.C.A., FMR LLC, FMR LLC, Nicholas Investment Partners LP, and SG Americas Securities LLC. View insider buying and selling activity for Esperion Therapeutics. Which major investors are buying Esperion Therapeutics stock? ESPR stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Wasatch Advisors Inc., Bellevue Group AG, Bamco Inc. NY, Goldman Sachs Group Inc., Platinum Investment Management Ltd., Sei Investments Co., and Mutual of America Capital Management LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben. View insider buying and selling activity for Esperion Therapeutics. How do I buy shares of Esperion Therapeutics? Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $37.52. How big of a company is Esperion Therapeutics? Esperion Therapeutics has a market capitalization of $1.04 billion and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe. What is Esperion Therapeutics' official website? The official website for Esperion Therapeutics is www.esperion.com. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
